Pure Global Completes Initial Sales License Review and Launches Groundbreaking Medical Cannabis Research Study with Appletree Medical Group
Pure Global Cannabis Inc. (TSX.V:PURE; OTC: PRCNF; FRA:1QS) (the “Company” or “Pure Global” or “PURE”) is pleased to announce that its wholly-owned subsidiary, PureSinse Inc. (“PureSinse”), has completed its initial Sales License review with Health Canada (“Sales License”) and has entered into a multi-year agreement with Appletree Medical Group Inc. (“Appletree” or “AMG”) pursuant to which Appletree will participate and provide lead investigators for the purposes of a real-world evidence-based research study.
Pure Global Cannabis Inc. (TSXV:PURE; OTC: PRCNF; FRA:1QS) (the “Company” or “Pure Global” or “PURE”) is pleased to announce that its wholly-owned subsidiary, PureSinse Inc. (“PureSinse”), has completed its initial Sales License review with Health Canada (“Sales License”) and has entered into a multi-year agreement with Appletree Medical Group Inc. (“Appletree” or “AMG”) pursuant to which Appletree will participate and provide lead investigators for the purposes of a real-world evidence-based research study.
Health Canada has now completed its initial review of PureSinse’s Sales License application requesting an amendment to its Access to Cannabis for Medical Purposes Regulations (“ACMPR”) license to add the activity of Sale of cannabis. PureSinse has confirmed with Health Canada it is now prepared to host an on-site the pre-Sales License inspection.
PureSinse has established capabilities and Standard Operating Procedures to meet licensing requirements for testing in compliance with Good Production Practices, child resistant packaging which meets the requirements of the Food and Drug Regulations. These include packaging, labelling, shipping methods, client registration, ordering and product record keeping systems in accordance with both requirements under the ACMPR and the Cannabis Act, which will be effective as of October 17, 2018.
Research Study with Appletree Medical Group
Appletree is one of the largest multidisciplinary community medical groups in Canada, serving more than 700,000 patients from its 35 medical centers in Ottawa and the GTA.
Together with Appletree and a leading Clinical Research Organization, PureSinse is launching a large-scale, peer-reviewed study on the efficacy of medical cannabis in the treatment of certain medical conditions.
The study will examine which cannabis strains and cannabinoid-terpene combinations provide improved therapeutic results for conditions such as neuropathic pain, insomnia, and anxiety disorders, as well as their effectiveness in reducing dependence on opioid medications in patients suffering from chronic pain disorders.
The observational data will guide the development of targeted pharmaceutical and wellness products. At the same time, the study will seek to provide the Canadian and international medical communities, as well as public health agencies, with relevant and valuable insights into the potential therapeutic effects of cannabis.
This partnership demonstrates our commitment to quality data, leading edge analytics, and evidenced-based research. It will be a leap forward for dramatic improvements in patient care. It will also help to expand our knowledge and our ability to develop sophisticated cannabis medicines for improving the lives of patients.
“We are excited about this important real-world study that will further develop our global understanding on the medical use of cannabis. It will ultimately allow physicians to make better decisions for prescribing cannabis from reputable, peer-reviewed clinical data, while providing valuable insights for developing unique cannabinoid-based pharmaceutical products,” said Malay Panchal, R.Ph., B.Sc.Phm., President & CEO of Pure Global.
“This partnership with PureSinse will help us answer many of the efficacy and safety questions surrounding medical cannabis. It will also help inform doctors about the appropriate prescribing of cannabis-based treatments, by providing an evidence-based understanding of the various products’ effects in clinical practice,” said Dr. Abhishek Raut, Medical Director at Appletree. “We are looking forward to working with the Pure Global team to expand our understanding and knowledge base, while making a significant and important contribution to the growing body of medical research regarding the use of medical cannabis.”
About Pure Global Cannabis
Pure Global Cannabis Inc. (TSX.V:PURE; OTC:PRCNF; FRA:1QS) is a vertically- integrated, growth-oriented life sciences cannabis company led by experienced pharma-industry, horticultural, consumer packaged goods (CPG), and supply chain experts. The Company’s wholly owned subsidiary, PureSinse Inc., is a licensed producer under the Access to Cannabis for Medical Purposes Regulations (ACMPR) focused on producing cannabis products for medical, wellness, health & beauty, natural health, and future legal adult use markets.
About Appletree Medical Group
Appletree Medical Group Inc. (AMG), founded in 1992, is one of Canada’s largest multidisciplinary medical groups, providing comprehensive care in Ottawa and the Greater Toronto Area. With its expansive network of family doctors and specialists, and telemedicine services for reaching patients in rural and remote areas, high-quality patient care is provided seven days a week. AMG is dedicated to providing the best environment for all types of practices: family doctors, specialists, acute care, and chronic disease management. Appletree is a two-time winner of ‘Best Medical Clinic’ in local media, and two-time winner of the Consumers’ Choice awards.
This news release contains certain forward-looking statements, including, but not limited to, statements about Pure Global’s future plans and intentions. Wherever possible, words such as “may”, “will”, “should”, “could”, “expect”, “plan”, “intend”, “anticipate”, “believe”, “estimate”, “predict” or “potential” or the negative or other variations of these words, or similar words or phrases, have been used to identify these forward-looking statements. These statements reflect management’s current beliefs and are based on information currently available to management as at the date hereof.
Forward-looking statements involve significant risk, uncertainties and assumptions. Many factors could cause actual results, performance or achievements to differ materially from the results discussed or implied in the forward-looking statements. These factors should be considered carefully and readers should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this news release are based upon what management believes to be reasonable assumptions, Pure Global cannot assure readers that actual results will be consistent with these forward-looking statements. These forward-looking statements are made as of the date of this news release, and Pure Global assumes no obligation to update or revise them to reflect new events or circumstances, except as required by law.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.
For further information: regarding Pure Global, please contact: Stephen Pynn, VP Corporate Development, Telephone: 1-866-899-PURE (7873), E-mail: email@example.com; Malay (Mel) Panchal, President & CEO, Telephone: 1-866-899-PURE (7873), E-mail: firstname.lastname@example.org